Table 2.
Base case results with PS model and Markov model from the Chinese and US perspectives.
| Factor | Chinese perspective (PS model) | US perspective (PS model) | ||||
|---|---|---|---|---|---|---|
| SG | Chemotherapy | Differences | SG | Chemotherapy | Differences | |
| LYs | 1.28 | 0.87 | 0.41 | 1.28 | 0.87 | 0.41 |
| QALYs | 0.87 | 0.52 | 0.35 | 0.87 | 0.52 | 0.35 |
| Drug costs | ¥2305982 | ¥439794 | ¥2266188 | $181706 | $10633 | $171073 |
| Overall Costs | ¥2501955 | ¥244112 | ¥2257842 | $304393 | $129000 | $175393 |
| ICER | ¥6375856 /QALY |
$501123 /QALY |
||||
| Chinese perspective (Markov model) | US perspective (Markov model) | |||||
| Factor | SG | Chemotherapy | Differences | SG | Chemotherapy | Differences |
| LYs | 1.24 | 0.84 | 0.40 | 1.27 | 0.89 | 0.38 |
| QALYs | 0.85 | 0.50 | 0.35 | 0.86 | 0.53 | 0.33 |
| Drug costs | ¥2261619 | ¥39319 | ¥2222300 | $181162 | $10556 | $170606 |
| Overall Costs | ¥2449455 | ¥235355 | ¥2214100 | $300940 | $131205 | $169735 |
| ICER | ¥6407626 /QALY |
$507416 /QALY |
||||
ICER, Incremental cost-effectiveness ratio; LYs, Life-years; PS, Partitioned survival model; QALYs, Quality-adjusted life-years; SG, Sacituzumab Govitecan; US, United States.